Lupin Limited ( (IN:LUPIN) ) has shared an update.
Lupin Limited reported strong financial performance for Q3 FY2025, with a 10.6% increase in sales and a 32.1% rise in EBITDA compared to the same quarter last year. The company achieved significant growth in its U.S. market, which contributed to its overall performance along with solid results from India and EMEA. Lupin aims to sustain this momentum in upcoming quarters through strategic sales growth and operational efficiencies.
More about Lupin Limited
Lupin Limited operates in the pharmaceutical industry, specializing in the development, production, and marketing of a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company has a strong market presence in the United States, India, and Europe, Middle East, and Africa (EMEA) regions, focusing on scaling new products and enhancing operational efficiencies.
YTD Price Performance: -8.25%
Average Trading Volume: 19,249
Current Market Cap: 1004.1B INR
Find detailed analytics on LUPIN stock on TipRanks’ Stock Analysis page.